Background E2805 was a phase III trial to test whether adjuvant sunitinib or sorafenib could improve disease-free survival compared to placebo in patients with renal cell carcinoma. Patient-reported outcomes (PRO), focusing on fatigue, were evaluated as a secondary endpoint. Patients and methods A total of 463 patients participated in the PRO study. Fatigue was measured by the FACIT Fatigue scale and PROMIS Fatigue SF1 measure at baseline, week 10, and week 22. The primary endpoint was change in fatigue score from baseline to week 22, measured by the FACIT Fatigue scale. Secondarily, the psychometric properties of PROMIS Fatigue SF1 were assessed in relation to the FACIT Fatigue scale. Results Fatigue got significantly worse on all arms after 2 cycles of treatment, and especially so in patients on sunitinib (− 9.6 vs. − 5.6 on sorafenib vs. − 4.7 on placebo). Fatigue remained stable during week 10 and week 22. Overall, the mean score change between baseline and week 22 was − 7.9 (p < 0.001) on sunitinib, − 6.4 (p < 0.001) on sorafenib and − 5.6 (p < 0.001) on placebo arm. The difference in score change was not statistically significant between the two experimental arms and the placebo arm (difference = − 2.34 [p = 0.110] and − 0.87 [p = 0.535] for sunitinib vs. placebo and sorafenib vs. placebo). PROMIS Fatigue SF1 had good internal consistency reliability and construct and criterion validity, and was highly correlated with the FACIT Fatigue scale score. Conclusions Fatigue got worse during study period, especially in patients on sunitinib. The PROMIS Fatigue SF1 was highly correlated with FACIT Fatigue and produced similar results.
Introduction
Fatigue is one of the most common symptoms among patients with renal cell carcinoma (RCC) [1] . Before 2006, cytokinebased therapies had been the standard of care for advanced RCC [2] but are associated with high rates of treatment-related fatigue [3] . In the past few years, several new target therapies have been developed and significantly improved progressionfree and overall survival in patients with advanced RCC [4] [5] [6] [7] . With the success in the metastatic setting, these targeted therapies, especially tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor and its related receptor (such as sorafenib [4, 8] and sunitinib [5, 8, 9] ), also have been or are being tested in the adjuvant setting. Fatigue remains a major toxicity with these targeted therapies [4, 5, [8] [9] [10] and can affect patient willingness to stay on therapy.
E2805 is one of the adjuvant trials comparing sunitinib and sorafenib versus placebo in patients with RCC [8] . Fatigue was one of the most common adverse events (others were hypertension, hand foot syndrome, and rash) leading to dose reduction in E2805. Consequently, the starting dosage was reduced for the two experimental drugs to manage a higher than desired dropout rate due to treatment intolerability. In clinical trials, including E2805, fatigue has been graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), which is dependent on the functional assessment of patients (i.e., interference in the activities of daily living) by investigators. Physicians often underreport treatment-related symptoms, and patients' self-evaluation of toxicity is recommended in clinical trials [11, 12] . Hence, at the time when the protocol was amended to reduce the starting dosage for the two experimental drugs, patient-reported outcome (PRO), focusing on fatigue, was added to E2805 as a secondary endpoint to fully capture the fatigue toxicity profile of the two TKIs using patients' own report. The inclusion of a placebo arm in the primary trial offers a unique opportunity to quantify the extent to which fatigue can be attributed to therapy, while controlling for multi-factorial factors that commonly contribute to cancer-related fatigue. Levels of fatigue were assessed using the FACIT Fatigue scale and the PROMIS Fatigue SF1 measure. The FACIT Fatigue scale measures the experience of fatigue and its impact on daily functioning, over a 1-week period. There are 13 items in the FACIT Fatigue scale, scored according to manualized instructions to produce a single total score. PROMIS Fatigue SF1 scale is a 7-item short form of the 95-item PROMIS fatigue item bank (notably, this 95 item bank includes the FACIT Fatigue scale within it). It is a more recently developed measure based upon item response theory (specifically the graded response model) and used the pattern of item responses for scoring, rather than the more traditional summation such as that used in the FACIT Fatigue. The intention going into this study was to use both questionnaires in order to compare their scores and relative responsiveness to change. The PROMIS Fatigue scale is shorter and more patient friendly; thus, if the two scores are highly correlated, and can produce similar results and same conclusion, it could support the more widespread use of the PROMIS Fatigue scale.
E2805 did not demonstrate superiority of sorafenib or sunitinib relative to placebo with regard to survival benefit among patients with high-risk RCC. However, the inclusion of patient-reported fatigue among a cohort of trial participants offers a unique opportunity to understand the fatigue toxicity profile of two commonly used TKIs, from patient's perspective, while controlling for expectancy and other confounding factors through the inclusion of a placebo arm. Here we report the PRO results of E2805.
Methods

Study design
E2805 (ClinicalTrials.gov identifier: NCT00326898), a double-blind, placebo-controlled, randomized phase III trial, was designed to evaluate possible improvement in diseasefree survival in locally advanced RCC patients randomly assigned to adjuvant sunitinib (arm A) or sorafenib (arm B) versus placebo (arm C) after radical or partial nephrectomy [8] . Secondary endpoints included overall survival, toxicity, and PRO. The primary purpose of the PRO study was to determine if there were differences in patient-reported fatigue, assessed by the validated FACIT Fatigue scale, between RCC patients randomized to either of the experimental arms compared to those randomized to placebo. Secondly, the study aimed to evaluate the psychometric properties of the PROMIS® Fatigue SF1measure, and to compare its performance with that of the FACIT Fatigue scale.
Patients
Patients were eligible for the study if they had histologically or cytological confirmed RCC, undergone a full surgical resection by open or laparosopic technique with negative margins; an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 and adequate cardiac, renal, and hepatic function. Key exclusion criteria included history of distant metastases, prior anti-cancer therapy in either adjuvant or neoadjuvant setting, or serious intercurrent illness [8] .The protocol was approved by the Institutional Review Boards at each registering institution. All patients provided written informed consent.
Treatment
Initially, patients were assigned to 50 mg sunitinib × 4 weeks with 2 weeks off, 800 mg sorafenib × 6 weeks, or placebo, but the starting dosage was reduced to manage a higher than desired dropout rate due to treatment intolerability after 1450 patients (target accrual goal of 1923 patients) had been enrolled. It was at this point that the PRO study was added to the trial. During the PRO part of the study, patients took sunitinib orally at 37.5 mg per day for 4 weeks followed by rest for 2 weeks (1 cycle = 6 weeks) or sorafenib orally at 400 mg once per day for 6 weeks or equivalent doses of placebo. After cycle 1 or 2, patients who had tolerable grade 2 side effects at worst were escalated to full doses of sunitinib 50 mg or sorafenib 400 mg orally twice daily in the same schedules. Patients who experienced grade 2 toxicities continued at the reduced starting dose level. Patients with grade 3 or 4 side effects had their dose modified in accordance with the specified dose modification guideline in the protocol. Patients on the placebo arm took the placebos in the same manner in terms of schedule, dose, and dose modification. Adverse events were graded using CTCAE, v4.0. In all arms, patients were treated for up to 9 cycles.
Assessment schedule and measurement of fatigue
FACIT Fatigue scale and the PROMIS Fatigue SF1 measure were administered as one PRO questionnaire at baseline (within 2 weeks prior to the start of protocol therapy), week 10 (day 28 of cycle 2), and week 22 (day 28 of cycle 4) after the start of protocol therapy, regardless of whether the patient had disease relapse or discontinued protocol therapy for any reason. The two follow-up assessment time points coincided with the completion of sunitinib in these cycles. If the assessment time point did not coincide with a scheduled clinic visit, patients were given a blank PRO questionnaire form and asked to complete it at home.
Per manual instructions, a prorated score for FACIT Fatigue was calculated for patients as long as patients responded to more than 50% of the items. The theoretical range of the prorated scale score is 0-52 with higher score indicating less fatigue. A score of less than 30 indicates severe fatigue. The PROMIS User Manual Version 1.1 was used to guide scoring of the PROMIS Fatigue SF1 measure. Briefly, the summed raw score was calculated first and then mapped to trait scores (standardized T-scores) in one-to-one correspondence using the score conversion table provided in the manual. T-score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The summed raw score for PROMIS Fatigue SF1 measure ranges 7-35, and the range of the corresponding standardized Tscores is 29.4-83.2. Higher score indicates more severe fatigue. The conversion table for PROMIS measure applies only when all question items on the form have been answered. Therefore, patients with missing items (< 2% in the study) had missing value for the standardized T-score and were excluded from corresponding analysis.
Statistical consideration
Since the impact of full-dose TKI inhibition on fatigue was the primary question of interest, FACIT Fatigue score change from baseline to the week 22 time point was the primary endpoint of the PRO study. The two experimental arms were compared to the placebo arm separately, and the overall type I error rate of two-sided 0.05 for the PRO study was equally split between the two comparisons. With 282 patients (94 patients in each arm) for the primary endpoint, the trial had about 80% power to detect a medium effect size (i.e., minimally important difference/standard deviation) of 0.45 using two sample t tests with a two-sided significance level of 0.025.
As stated previously, after the starting dose was amended all subsequent patients were eligible to participate in the PRO study to achieve the above sample size, assuming about 75% participation rate of the PRO study and 80% of attrition rate at the week 22 assessment.
Changes in the fatigue scores between baseline and followup visits were examined using paired t test and compared between treatment arms using two sample t tests. At each time point, fatigue scores were compared between the treatment arms using Wilcoxon rank-sum test. All patients with fatigue data at the specific time point were included in the analysis. Multivariable linear mixed effects models with random intercept (repeated measures within single patients with unstructured covariance matrices) were fit using the maximum likelihood method to estimate the time profile of fatigue and to assess the treatment difference in fatigue over time, after adjusting other covariates (age, sex, ECOG PS, fatigue prior to surgery, fatigue after surgery, disease discovery, history of cardiovascular disease), assuming that any missing data were missing at random. Time points were coded as categorical variable in the mixed effect models. Patients with at least one assessment were included in these models.
The psychometric properties of the PROMIS Fatigue SF1 measure were assessed. Cronbach coefficient α was computed to estimate the internal consistency reliability. Known-group validity and exploratory factor analysis were conducted to check construct validity. The area under the receiver operating characteristics (ROC) curve was used to examine the criterion validity, and severity of fatigue (severe vs. non-severe fatigue) defined by FACIT Fatigue scale score was used as the dependent variable in the logistic regression model. Spearman's and Pearson correlation coefficients were used to explore the association between scores on the FACIT Fatigue scale and PROMIS Fatigue SF1 measure.
All tests were two-sided, p < 0.025 was considered statistically significant for the two primary endpoints. No adjustment was made for multiplicity and p < 0.05 was used for statistical significance for other endpoints. STATA 13.1 was used to conduct all the analyses.
Results
Patients
A total of 1943 patients were enrolled to E2805 between April 24, 2006 and September 1, 2010 [8] , and 463 patients participated in the PRO study and reported their fatigue level at one or more time points. Of them, 418 (90.3%) patients reported data about fatigue at baseline; 45 patients had missing data at baseline but reported some data about fatigue at week 10 and/ or week 22 assessments. Taking all three visits together, the most common reason for missing fatigue data was patient not given form by staff (n = 90), and very few patients had missing data due to patient illness (n = 7) or death (n = 2). This report was based on data as of April 14, 2015.
Fatigue measured by FACIT Fatigue scale
Of the 418 patients who reported their fatigue level at baseline, 381(91.1%) patients reported fatigue data at week 10 assessment, and 328(78.5%) patients reported fatigue data at week 22 assessment using FACIT Fatigue scale. Furthermore, two patients at week 10 and 7 patients at week 22 were excluded from the corresponding analyses due to having ≥ 7 items in the FACIT Fatigue scale unanswered. A total of 321 patients (107 on sunitinib, 95 on sorafenib, 119 on placebo) had score for FACIT Fatigue at both baseline and week 22 assessments and were the primary analysis population for the PRO study. Treatment arms were well balanced regarding patient characteristics in the 321 patients ( Table 1 ). The 321 patients also had similar characteristics compared to the 142 patients included in the PRO study but did not have fatigue data at both baseline and week 22, and the 1480 patients who did not participate in the PRO study (Supplemental Table S1 ).
As expected, patients had similar fatigue level at baseline in the three arms with average FACIT Fatigue score of 42.5 (SD = 9.0) in the overall sample (Supplemental Table S2 ). This is a baseline level of fatigue comparable to that of the general US population [13] . After 10 weeks of treatment, fatigue score reduced (fatigue worsened) on all three arms (Fig. 1a) . The mean score change between week 10 and baseline was − 9.6 (p < 0.001) on sunitinib, − 5.6 (p < 0.001) on sorafenib, and −4.7 (p < 0.001) on placebo arm. The difference in score change (4.9, p < 0.001) between the sunitinib arm and the placebo arm reached statistical significance. During week 10 and week 22, fatigue level remained stable in all arms. Overall, the mean score change between week 22 and baseline was − 7.9 (p < 0.001) on sunitinib, − 6.4 (p < 0.001) on sorafenib and − 5.6 (p < 0.001) on placebo arm, and the difference in score change was not statistically significant between the two experimental arms and the placebo arm ( Table 2) . Linear mixed effect model analysis showed similar results (data not shown).
Patient-reported fatigue using FACIT Fatigue was crosschecked with investigator-reported fatigue via CTCAE during cycle 2 (week 10) and cycle 4 (week 22). In both assessments, about a quarter of patients had FACIT Fatigue score < 30 (severe fatigue) while the CTCAE fatigue grade was zero (Supplemental Fig. S1 ). At cycle 2, 5.6% (6/107) of patients with FACIT Fatigue score < 30 had CTCAE fatigue grade of 3, the proportion was 4.0% (4/101) for cycle 4 assessment. Table S2, Table 2 , and Fig. 1b ).
Psychometric properties of the PROMIS Fatigue SF1 scale
Internal consistency (Cronbach's alpha) of the PROMIS Fatigue SF1 measure was 0.85 at baseline, 0.88 at week 10 and 0.90 at week 22 assessments. Using the FACIT Fatigue score as the criterion, the area under the ROC curve for PROMIS Fatigue standardized T-score was 0.96 at baseline, 0.94 at week 10, and 0.96 at week 22. As expected, patients with performance status (PS) of 1 had higher (worse) fatigue score than patients with PS = 0, and patients with fatigue present at surgery had more severe fatigue than patients without fatigue at surgery (Supplemental Table S3 ). In the exploratory factor analysis, the first factor accounted for most of the variance (92.6%) in a two-factor model, and only the first factor had eigenvalue > 1 (3.77 vs. 0.30 for the second factor). Loadings on the first factor (0.32-0.86) were both high and similar to the loadings for a 2-factor solution (0.31-0.86). These results suggest that the PROMIS Fatigue SF1 measure is, as previously demonstrated [14, 15] , unidimensional. The PROMIS Fatigue standardized T-scores and FACIT Fatigue scores were highly correlated. The Spearman's correlation coefficient between the two scores was 0.83 at baseline, 0.90 at week 10, and 0.89 at week 22 assessments. The Pearson correlation coefficient between the two scores was quite similar (0.83, 0.89, and 0.88, respectively).
Discussion
We examined fatigue level in patients with unfavorable RCC using the well-validated FACIT Fatigue scale and the more recently developed PROMIS Fatigue SF1 measure. The results show that the study patients had levels of fatigue comparable to the US general population when entering the study [13] , probably due to their clinical status at the time (diseasefree, locally advanced RCC with no prior radiation and systemic therapy, ECOG performance status of 0-1). With 2 cycles of treatment, fatigue got significantly worse in all patients. In patients with placebo, fatigue score worsened by 4.7 (SD = 9.0) between baseline and week 10, while fatigue score worsened by 9.6 (SD = 11.5) during the same time period in patients receiving sunitinib. The difference in score change between the two arms were both statistically significant and above the minimal clinically important difference [16, 17] . Given the clinical status of these patients at baseline, the timing of the assessment and the inclusion of the placebo arm, the worsening of fatigue can be attributed to sunitinib. During week 10 and week 22 (cycles 3 and 4), fatigue level remained relatively stable in the two arms. These results suggest that sunitinib could cause fatigue in study patients. For patients who received sorafenib, fatigue score worsened by 5.6 and 6.4 at week 10 and week 22 assessments, respectively. It was not statistically significant compared to placebo. These results suggest that sorafenib is unlikely causing any severe fatigue in the study patients.
In the previously published report of the trial [8] , fatigue was shown to be one of the most common grade 3 or worse adverse events associated with sunitinib (18%) reported via NCI CTCAE v4.0 (7% on sorafenib, and 3% on placebo). Fatigue (all grades 36.6%) was also reported as one of the most common adverse events in patients receiving sunitinib for their locoregional RCC at high risk for tumor recurrence after nephrectomy in another trial [9] . The incidence of grade 3 or worse fatigue (4.9% on sunitinib vs. 1.3% on placebo) was much lower though [9] . The current PRO analysis provides consistent results from the patient perspective, but it also demonstrated the substantial discordance and underreporting of fatigue by CTCAE compared to PRO.
PROMIS Fatigue SF1 measure is a short form of the PROMIS Fatigue item bank; so is the FACIT Fatigue scale. Notably, and supported by these reports, PROMIS fatigue item bank had clinical validity across diverse conditions, including cancer [18] . In this study, the short form PROMIS Fatigue SF1 measure was shown to have good internal consistency reliability and criterion and construct validity. PROMIS Fatigue SF1 score is highly correlated with the FACIT Fatigue score. The distribution, overall trend over time and comparison of fatigue between treatment arms showed quite similar results using PROMIS Fatigue standardized Tscore compared to that assessed via the validated FACIT Fatigue scale. This suggests that the two measures can be used interchangeably in oncology clinical research.
The trial had excellent compliance rate for the PRO study. The most common reason for missing fatigue data was patient not given form by staff. Very few patients had missing data due to illness. Missing data did not pose a serious problem for PRO comparisons between the treatment arms in this study. The patients included in the PRO study had similar patient characteristics compared to those who did not participate in the PRO study. The inclusion of placebo arm allowed the precise evaluation of treatmentrelated fatigue versus disease-related fatigue. Nevertheless, the study has limitations to note. Particularly, only two follow-up time points were assessed in the study, and it is not known whether fatigue would continue to deteriorate or remain relatively stable with continuous treatment or resolve after treatment discontinuation. In addition, the time point of week 10 (at the completion of 4 weeks of sunitinib therapy and during continuous sorafenib dosing in cycle 2) was expected to allow exploration of the association between dose escalation and side effects had all or most patients had their dose escalated in cycle 3 (week 10 was right prior to the dose escalation and week 22 reflected 2 cycles of treatment at the escalated full dose of both agents if done in this case). The data, however, showed that about a quarter of patients did not have dose escalation and half of patients escalated their dose starting cycle 2. Thus, the association between dose escalation and side effects was not able to be precisely evaluated in the study. The PRO study was added after the parent trial was activated for 3 years: It is possible that physician management of fatigue may have improved at that point, making fatigue toxicity worse in the early phase of the trial, than in the current estimates in the PRO study. The incidence of fatigue reported via CTCAE, however, did not differ in patients enrolled before PRO study compared to those enrolled after PRO study (data not shown). For many reasons, the results reported here are not to be taken as a definitive comparison of sorafenib and sunitinib with regard to their overall tolerability. First, the study was designed to test each drug against placebo, not as a head-tohead comparison. Second, there are other toxicities associated with this class of therapy (e.g., hand foot syndrome; diarrhea) that can have adverse effects on patients' lives and therefore influence tolerability. Finally, the starting doses tested in this study (37.5 mg sunitinib; 400 mg sorafenib), may not be the mono-therapeutic doses used in practice. Instead, the value of this report lies in the demonstration of the measurable worsening of fatigue that occurs when treating otherwise relatively asymptomatic patients with these agents, and in the demonstration of the high degree of consistency in results whether one uses FACIT Fatigue scale or the PROMIS Fatigue SF1 measure.
In conclusion, sunitinib was associated with significant fatigue after 2 cycles of treatment and fatigue continues until end of cycle 4, when it was no longer statistically significant though. The increased fatigue associated with sorafenib was modest relative to placebo at both time points and did not reach statistical significance. The FACIT Fatigue scale and the PROMIS Fatigue SF1 measure both performed well and very similarly to each other, suggesting that either one is a valid measure for future studies.
